Background
cmrf-logo

New research from the National Children’s Research Center, funded by the Children’s Medical Research Foundation (CMRF), has identified a link between child obesity and decreased effectiveness in the innate immune system among obese children.

The research, published in the Journal of Clinical Endocrinology and Metabolism, showed that one of the most important immune cells in the innate immune system – the invariant natural killer T cell – was much reduced in number and much less effective at doing its basic job in obese children.

According to Dr Declan Cody, senior paediatrician said, “This cell – the invariant natural killer T cell – has been described as a sensor and manager of inflammation, and when deficient or defective has been linked to cardiovascular disease and cancer, so to see it already disappearing in children who are obese, is really worrying for their future risk”.

The study included 49 children from 6 to 16 years of age and showed that the children are switching on two types of genes that have been shown to be involved in type 2 diabetes and heart disease in adults. “These are very disturbing but fascinating findings” added Professor Carlos Blanco, head of the National Childrens Research Center, which funded the research.

Professor Blanco added: “The findings ultimately may allow us to predict those children most at risk of developing adult disease and therefore to target our interventions. In addition this work shows that the process of developing type 2 diabetes is well and truly underway at a genetic level in children as young as 6 years of age who are allowed to become obese”.

Professor Donal O’Shea, lead author on the study and Chairs the Royal College of Physicians of Ireland policy group on obesity.  He has presented the findings to the European Union Ministers for Health and The Coca Cola Company and said “These findings must be used to inform individuals, public policy and industry behaviour when it comes to our patterns of physical activity and food and drink consumption which are the main drivers of weight in children”.

rcsigarryduffy

A consortium led by the Royal College of Surgeons in Ireland (RCSI) and the new Science Foundation Ireland centre Amber has received €8.7m funding for research into heart disease.

Called Amcare (Advanced Materials for Cardiac Regeneraton), the group involves ten partners from five European countries and the funding is part of the EU’s Framework Programme 7.

The Amcare programme, which will create ten new positions, will carry out research to develop natural materials and new surgical devices to enhance the delivery of the body’s own stem cells to the heart to promote healing after a heart attack and prevent premature death.

The therapies being developed will replace heart cells that die due to the reduced blood flow that occurs during a heart attack, with new healthy cells derived from stem cells that come from the patient’s own bone marrow.

Amcare is co-ordinated by Dr Garry Duffy, Department of Anatomy and Tissue Engineering Research Group, RCSI and Amber investigator.

He said: “Regenerative medicine and stem cell therapies have the potential to revolutionise the treatment of patients who have suffered a heart attack, and through Amcare we will develop new technologies to enhance stem cell therapies for these patients by increasing targeting and ease of delivery using advanced biomaterials.